Could an arthritis pill ease Sjogren's? new trial seeks answers
NCT ID NCT07281456
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether tofacitinib, a drug already used for rheumatoid arthritis, is safe and helpful for people with Sjogren's disease. About 60 adults with mild-to-moderate Sjogren's will take the pill twice daily for 28 weeks. Researchers will track side effects and measure changes in symptoms like dry eyes, joint pain, and overall disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tofacitinib (a pill that calms the immune system, already approved for rheumatoid arthritis)
What this could lead to
If it works, this could point toward a new treatment option for people with Sjogren's disease, helping control symptoms like dry eyes, joint pain, and fatigue.
What could go wrong
This is an early phase 2 trial with only 60 people, so results may not apply to everyone. Tofacitinib can increase risk of infections and other side effects, and it may not work for Sjogren's as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••